Slide 1: ASX Announcement: Investor Webinar Presentation
ASX Announcement ASX : ENP 28 August 2026 Investor Webinar Presentation Melbourne, Australia – Entropy Neurodynamics Limited (‘Entropy Neurodynamics’ or the ‘Company’) (ASX: ENP), is pleased to provide the attached Investor Webinar Presentation, which will be presented today by Jason Carroll, Chief
Slide 2: Risks associated with Psilocin; Forward-Looking Information
Risks associated with Psilocin All medicines carry risks and specialist prescribers, such as registered psychiatrists are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of psilocybin and si
Slide 3: Achieving Leadership in the Treatment of Neuropsychiatry Disorders
For personal use only Achieving Leadership in the Treatment of Neuropsychiatry Disorders Jason Carroll – CEO & Managing Director ASX : ENP ASX : ENPO August 2026 ENTROPY NEURODYNAMICS: World- This presentation has been authorised for release by the Board of Entropy Neurodynamics First ClinicalLimite
Slide 4: Disclaimers
Disclamers The information contained in this presentation (the “Presentation”) has been prepared by Tryp Therapeutics Inc. (“Tryp” or the “Company”) and contains information pertaining to the business, operations and assets of the Company. The information contained in this Presentation (a) is provid
Slide 5: Overview and Investment Thesis
Overview and Investment Thesis For personal use only A unique next-generation Large addressable markets psychedelic platform: & strong IP protection • Lead asset, TRP-8803 is a proprietary IV-infusion platform • TRP-8803 targets multiple neuropsychiatric disorders with high therapy that delivers a r
Slide 6: Corporate Overview
Corporate Overview Shareholder Overview Corporate Snapshot Shareholder register as at 3 July 2026 For personal use only ASX CODE SHARES ON ISSUE DEBT ENP 1.6Bn Nil ADDITIONAL FUNDING MARKET CAPITALISATION CASH AT BANK ACCESSIBLE THROUGH OPTIONS AU$ 58.8m at $0.036 per share AU$ 5.6m at 30 June 2026
Slide 7: Previous oral psilocybin studies underpin confidence in TRP-8803
Compelling treatment-resistant data from previous oral psilocybin studies underpin confidence in TRP-8803 as a precision therapy platform FM BED IBS For personal use only Fibromyalgia Binge Eating Disorder Irritable Bowel Syndrome Chronic Pain associated with Greater than 2 BE IBS-Symptom 4 body sec
Slide 8: Variability and inconsistency of oral psilocybin vs TRP-8803
Variability and inconsistency of oral psilocybin vs TRP-8803 For personal use only Oral Psilocybin* TRP-8803 (IV Psilocin) Note: Vertical lines represent time (mins) post-dose ENTROPY NEURODYNAMICS: Advancing Psychedelic Science for Disorders in Neuropsychiatry
Slide 9: TRP-8803 has been designed to remove the barriers to therapy
TRP-8803 has been specifically designed to remove the barriers to therapy TRP-8803 : A Precision approach in Neuropsychiatry For personal use only Oral Psilocybin* IV-infused Psilocin Short treatment duration of 1-2 hours ✕ ~8-10 hours ✓ Quick onset of psychedelic ✕ 1-2 hours ✓ state (~15 minutes) P
Slide 10: TRP-8803 trial in treatment-resistant Binge-Eating Disorder
Phase 2 TRP-8803 trial in treatment-resistant Binge-Eating Disorder (BED) For personal use only OVERVIEW KEY EFFICACY MEASURES PRIMARY ENDPOINT Phase 2, open-label clinical trial in collaboration with Changes in binge eating Safety and tolerability Swinburne University frequency, binge eating severi
Slide 11: Landmark trial results validate TRP-8803
Landmark trial results validate TRP-8803 as a potential treatment 50% CLINICAL For personal use only REMISSION TRP-8803 delivered 50% remission in treatment-resistant BED and clinical 100% improvement in 100% of patients CLINICALLY MEANINGFUL IMPROVEMENT Clinical safety and efficacy results represen
Slide 12: Additional, highly compelling findings
Additional, highly compelling findings For personal use only Depression Quality of Life Anxiety Clinical Global Next 57% reduction 63% improvement 58% reduction in Impression Q4 CY26 Results in Depression in quality of life Anxiety (GAD-7) Clinical Global from cohort 2 (12 (PHQ-9) Impression patient
Slide 13: Strategic significance
Strategic significance For personal use only Results validate TRP-8803 Significantly de-risks the Strengthens regulatory Provides additional data via EEG as a differentiated TRP-8803 development and partnering discussions analysis identifying a mechanistic precision-controlled program and progressio
Slide 14: World-first patient basket study across eight disorders
World-first 72 patient basket study across eight neuropsychiatric and pain disorders Evaluating TRP-8803 indications in parallel, rather than one indication at a time. For personal use only 72 PATIENTS 8 DISORDERS 9 COHORTS 1 PROTOCOL SELECTED FOR SHARED NEUROBIOLOGY Treatment-Resistant Post-Traumat
Slide 15: US Phase 2 MDD Trial: TRP-8803 vs escitalopram
US Phase 2 MDD Trial: TRP-8803 vs escitalopram Head-to-Head Clinical Design: Why this study is different: For personal use only • Pre-clinical Trial Agreement signed with UCSF to develop a • The study moves TRP8803 earlier in the depression-treatment Phase 2 study in up to 80 young adults with Major
Slide 16: TRP-8803 Clinical Development Pathway
TRP-8803 Clinical Development Pathway From broad clinical signals to prioritised US development A data-driven strategy designed to build one regulatory platform and multiple development pathways For personal use only DISCOVER PRIORITISE ENABLE EXECUTE EXPAND 1 Broad clinical 2 Select strongest signa
Slide 17: Global pharma chasing differentiated Phase 2 assets
Global pharma chasing differentiated Phase 2 assets on minimal patient data AUGUST 25, 2025 JUNE 13, 2026 JULY 16, 2026 AUGUST 18, 2026 For personal use only AbbVie tunes in to Gilgamesh's Otsuka buys Transcend in $1.2B Lilly buys AtaiBeckley for $2.8B Johnson & Johnson to lead a US$85m story, inkin
Slide 18: Psychedelic Companies: Market Cap/Deal size vs market opportunity
Psychedelic Companies (Market Cap/Deal size vs market opportunity) Clinical Phase vs Valuation | Bubble size ≈ estimated total addressable market of targeted disorders (in USD) For personal use only Bubble size ≈ Addressable Market 5,000 Smaller TAM Definium (DFTX) Medium TAM $4,558m Larger TAM 4,00
Slide 19: Aggressive absorption of global IP rights
Aggressive absorption of global IP rights Patent applications and trade secrets based on novel methods for manufacturing, formulation, dosing and treatment of specific disease indications have been filed for all major global pharmaceutical markets For personal use only BINGE EATING DISORDER FIBROMYA
Slide 20: TRP-8803 has three major growth categories for commercialisation
TRP-8803 has three major growth categories for commercialisation For personal use only Psychiatry Pain Gastroenterology Maximum efficacy 40-60% across conditions 30-40% in non-treatment resistant 20-40% in non-treatment resistant of standard of care: population – limited long-term use population due
Slide 21: Multiple pending value catalysts
Multiple pending value catalysts HREC approval granted Q3 CY26 Q4 Q4CY26 CY26 Ongoing Q2 CY27 For personal use only Commencement of Completion Completion of cohort 2 dosing2indosing Phase 2 Planned cohort 2 dosing in cohort inBED Development of of commencement 72 trial 2 BED trial Phase Phase 2 BED
Slide 22: Contact
Jason Carroll Chief Executive Officer For personal use only jcarroll@tryptherapeutics.com Henry Jordan Six Degrees Investor Relations henry.jordan@sdir.com.au CONTACT WEBSITE: entropyneurodynamics.com SOCIALS: X (Twitter) @tryptherapeutic